[1]
|
Dosani, T., Covut, F., Pinto, R., Kim, B.-G., Ali, N., Beck, R., et al. (2019) Impact of Lenalidomide on Collected Hematopoietic Myeloid and Erythroid Progenitors: Peripheral Stem Cell Collection May Not Be Affected. Leukemia & Lymphoma, 60, 2199-2206. https://doi.org/10.1080/10428194.2019.1573367
|
[2]
|
郭秋霞, 王吉刚, 刘彦琴, 刘景华, 张美玉, 李敏燕, 等. 来那度胺对多发性骨髓瘤患者自体移植造血干细胞采集影响[J]. 临床军医杂志, 2021, 49(1): 37-39, 43.
|
[3]
|
Sonneveld, P., Goldschmidt, H., Rosiñol, L., Bladé, J., Lahuerta, J.J., Tacchetti, M.C., et al. (2013) Bortezomib-Based versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients with Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. Journal of Clinical Oncology, 31, 3279-3287. https://doi.org/10.1200/JCO.2012.48.4626
|
[4]
|
Huang, B., Tan, Y., Zhao, W.-H., Zeng, Q.-C., Li, B.-S. and Chen, R.-L. (2014) How to Determine Bortezomib-Based Regimen for Elderly Patients with Multiple Myeloma: PAD versus CBd, an Observational Study. Journal of Cancer Research and Clinical Oncology, 140, 303-309. https://doi.org/10.1007/s00432-013-1570-6
|
[5]
|
Kazandjian, D., Korde, N., Mailankody, S., Hill, E., Figg, W.D., Roschewski, M., et al. (2018) Remission and Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. JAMA Oncology, 4, 1781-1783.
https://doi.org/10.1001/jamaoncol.2018.5457
|
[6]
|
Laubach, J.P. and P.G. (2015) Richardson, CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. Clinical Cancer Research, 21, 2660-2662. https://doi.org/10.1158/1078-0432.CCR-14-3190
|
[7]
|
Mateos, M., Cavo, M., Blade, J., Dimopoulos, M.A., Suzuki, K., Jakubowiak, A., et al. (2020) Overall Survival with Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 395, 132-141. https://doi.org/10.1016/S0140-6736(19)32956-3
|
[8]
|
Attal, M., Harousseau, J.-L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., et al. (2006) Maintenance Therapy with Thalidomide Improves Survival in Patients with Multiple Myeloma. Blood, 108, 3289-3294.
https://doi.org/10.1182/blood-2006-05-022962
|
[9]
|
McCarthy, P.L., Owzar, K., Hofmeister, C.C., Hurd, D.D., Hassoun, H., Richardson, P.G., et al. (2012) Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 366, 1770-1781.
https://doi.org/10.1056/NEJMoa1114083
|
[10]
|
Pulte, E.D., Dmytrijuk, A., Nie, L., Goldberg, K.B., McKee, A.E., Farrell, A.T., et al. (2018) FDA Approval Summary: Lenalidomide as Maintenance Therapy after Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma. The Oncologist, 23, 734-739. https://doi.org/10.1634/theoncologist.2017-0440
|
[11]
|
Dimopoulos, M.A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K.C., et al. (2019) Oral Ixazomib Maintenance Following Autologous Stem Cell Transplantation (TOURMALINE-MM3): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial. Lancet, 393, 253-264. https://doi.org/10.1016/S0140-6736(18)33003-4
|
[12]
|
Dimopoulos, M.A., Špička, I., Quach, H., Oriol, A., Hájek, R., Garg, M., et al. (2020) Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology, 38, 4030-4041.
https://doi.org/10.1200/JCO.20.02060
|
[13]
|
Alsina, M., et al. (2012) A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research, 18, 4830-4840. https://doi.org/10.1158/1078-0432.CCR-11-3007
|
[14]
|
Siegel, D.S., Dimopoulos, M.A., Ludwig, H., Facon, T., Goldschmidt, H., Jakubowiak, A., et al. (2018) Improvement in Overall Survival with Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 36, 728-734. https://doi.org/10.1200/JCO.2017.76.5032
|
[15]
|
Moreau, P., Mateos, M.-V., Berenson, J.R., Weisel, K., Lazzaro, A., Song, K., et al. (2018) Once Weekly versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Interim Analysis Results of a Randomised, Phase 3 Study. Lancet Oncology, 19, 953-964.
https://doi.org/10.1016/S1470-2045(18)30354-1
|
[16]
|
Chari, A., Martinez-Lopez, J., Mateos, M.-V., Bladé, J., Benboubker, L., Oriol, A., et al. (2019) Daratumumab Plus Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 134, 421-431.
https://doi.org/10.1182/blood.2019000722
|
[17]
|
Dimopoulos, M.A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., et al. (2016) Carfilzomib and Dexamethasone versus Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (ENDEAVOR): A Randomised, Phase 3, Open-Label, Multicentre Study. Lancet Oncology, 17, 27-38.
https://doi.org/10.1016/S1470-2045(15)00464-7
|
[18]
|
Bazou, D., Le, G., Boyle, A., Blum, A. and O’Gorman, P. (2020) Marizomib: A Novel Therapeutic Approach for the Treatment of Central Nervous System Myeloma. eJHaem, 1, 315-317. https://doi.org/10.1002/jha2.72
|
[19]
|
Richardson, P.G., Zimmerman, T.M., Hofmeister, C.C., Talpaz, M., Chanan-Khan, A.A., et al. (2016) Phase 1 Study of Marizomib in Relapsed or Relapsed and Refractory Multiple Myeloma: NPI-0052-101 Part 1. Blood, 127, 2693-2700.
https://doi.org/10.1182/blood-2015-12-686378
|
[20]
|
Richardson, P.G., Oriol, A., Beksac, M., Liberati, A.M., Galli, M., Schjesvold, F., et al. (2019) Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): A Randomised, Open-Label, Phase 3 Trial. Lancet Oncology, 20, 781-794.
https://doi.org/10.1016/S1470-2045(19)30152-4
|
[21]
|
Garderet, L., Kuhnowski, F., Berge, B., Roussel, M., Escoffre-Barbe, M., Lafon, I., et al. (2018) Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed Multiple Myeloma. Blood, 132, 2555-2563.
https://doi.org/10.1182/blood-2018-07-863829
|
[22]
|
Dimopoulos, M.A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M.S., Richardson, P.G., Popa McKiver, M., Jou, Y.M., Shelat, S.G., Robbins, M., Rafferty, B. and San-Miguel, J. (2018) Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 379, 1811-1822. https://doi.org/10.1056/NEJMoa1805762
|
[23]
|
Dimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., et al. (2020) Carfilzomib, Dexamethasone, and Daratumumab versus Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CANDOR): Results from a Randomised, Multicentre, Open-Label, Phase 3 Study. The Lancet, 396, 186-197.
https://doi.org/10.1016/S0140-6736(20)30734-0
|
[24]
|
Attal, M., Richardson, P.G., Vincent Rajkumar, S., San-Miguel, J., Beksac, M., Spicka, I., et al. (2019) Isatuximab plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study. Lancet, 394, 2096-2107. https://doi.org/10.1016/S0140-6736(19)32556-5
|
[25]
|
Popat, R., Brown, S.R., Flanagan, L., Hall, A., Gregory, W., Kishore, B., et al. (2016) Bortezomib, Thalidomide, Dexamethasone, and Panobinostat for Patients with Relapsed Multiple Myeloma (MUK-Six): A Multicentre, Open-Label, Phase 1/2 Trial. Lancet Haematoogy, 3, e572-e580. https://doi.org/10.1016/S2352-3026(16)30165-X
|
[26]
|
Rosinol, L., Oriol, A., Rios, R., Sureda, A., Blanchard, M.J., Hernández, M.T., et al. (2019) Bortezomib, Lenalidomide, and Dexamethasone as Induction Therapy Prior to Autologous Transplant in Multiple Myeloma. Blood, 134, 1337-1345. https://doi.org/10.1182/blood.2019000241
|
[27]
|
Sadelain, M., Riviere, I. and Riddell, S. (2017) Therapeutic T Cell Engineering. Nature, 545, 423-431.
https://doi.org/10.1038/nature22395
|
[28]
|
Trudel, S., Lendvai, N., Popat, R., Voorhees, P.M,, Reeves, B., Libby, E.N., et al. (2018) Targeting B-cell Maturation Antigen with GSK2857916 Antibody-Drug Conjugate in Relapsed or Refractory Multiple Myeloma (BMA117159): A Dose Escalation and Expansion Phase 1 Trial. The Lancet Oncology, 19, 1641-1653.
https://doi.org/10.1016/S1470-2045(18)30576-X
|
[29]
|
Lonial, S., Lee, H.C., Badros, A., Trudel, S., Nooka, A.K., Chari, A., et al. (2020) Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study. Lancet Oncology, 21, 207-221. https://doi.org/10.1016/S1470-2045(19)30788-0
|
[30]
|
Chng, W.J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., et al. (2014) IMWG Consensus on Risk Stratification in Multiple Myeloma. Leukemia, 28, 269-277. https://doi.org/10.1038/leu.2013.247
|
[31]
|
Sonneveld, P., Schmidt-Wolf, I.G., van der Holt, B., El Jarari, L., Bertsch, U., Salwender, H., et al. (2012) Bortezomib Induction and Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. Journal of Clinical Oncology, 30, 2946-2955.
https://doi.org/10.1200/JCO.2011.39.6820
|
[32]
|
Bianchi, G., Richardson, P.G. and Anderson, K.C. (2014) Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area. Journal of Clinical Oncology, 32, 2125-2132. https://doi.org/10.1200/JCO.2014.55.7900
|
[33]
|
Nooka, A.K., Kaufman, J.L., Muppidi, S., Langston, A., Heffner, L.T., Gleason, C, et al. (2014) Consolidation and Maintenance Therapy with Lenalidomide, Bortezomib and Dexamethasone (RVD) in High-Risk Myeloma Patients. Leukemia, 28, 690-693. https://doi.org/10.1038/leu.2013.335
|